PCI-32765 (Ibrutinib)Catalog No. A11020

Quick Overview

PCI-32765 is an orally bioavailable small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity.
Products are for laboratory research use only. Not for human use. We do not sell to patients.

PCI-32765 (Ibrutinib)

Product Information
Catalog Num A11020
M. Wt 440.5
Formula C25H24N6O2
Solubility DMSO
Purity >98%
Storage at -20°C 3 years Powder
CAS No. 936563-96-1
Synonyms Ibrutinib
Chemical Name 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one
SMILES Code C=CC(=O)N1CCC[[email protected]](C1)N2C3=C(C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=NC=N3)N

Biological activity
PCI-32765 is an orally bioavailable small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity.
Target Value
BTKIC50: 0.5nM
BLKIC50: 0.5nM
BmxIC50: 0.8nM
CSKIC50: 2.3nM
FGRIC50: 2.3nM
BRKIC50: 3.3nM
HckIC50: 3.7nM
EGFRIC50: 5.6nM
YESIC50: 6.5nM
ErbB2IC50: 9.4nM
ITKIC50: 10.7nM
JAK3IC50: 16.1nM
FRKIC50: 29.2nM
LCKIC50: 33.2nM
RETIC50: 36.5nM
FLT3IC50: 73nM
TECIC50: 78nM
AblIC50: 86nM
FynIC50: 96nM
RIPK2IC50: 152nM
c-SrcIC50: 171nM
LynIC50: 200nM
PDGFRαIC50: 718nM
FmsIC50: 5.545μM
FERIC50: 8.07μM
JAK1IC50: >10μM
JAK2IC50: >10μM
NEK2IC50: >10μM
p38IC50: >10μM
PI3KIC50: >10μM
PLK1IC50: >10μM
RSK1IC50: >10μM
SykIC50: >10μM
Solubility (25C) * In vitro DMSO 88 mg/mL (199.77 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 1% DMSO/30% polyethylene glycol/1% Tween 80 12 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.



[1]. Pan, Z; Scheerens, H; Li, SJ; Schultz, BE; Sprengeler, PA; Burrill, LC; Mendonca, RV; Sweeney, MD; Scott, KC; Grothaus, Paul G.; Jeffery, Douglas A.; Spoerke, Jill M.; Honigberg, Lee A.; Young, Peter R.; Dalrymple, Stacie A.; Palmer, James T. (2007). “Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase”. ChemMedChem 2 (1): 58–61.

[2]. Honigberg, LA; Smith, AM; Sirisawad, M; Verner, E; Loury, D; Chang, B; Li, S; Pan, Z; Thamm, DH; Miller, RA; Buggy, JJ (2010). “The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy”. Proceedings of the National Academy of Sciences of the United States of America 107 (29): 13075–80.

[3]. Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, Keating MJ, O’Brien S, Chiorazzi N, Burger JA (2012). The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo 119. Blood. pp. 1182–1189.


Return Policy Contact information
Adooq Bioscience has Satisfaction Guarantee return policy. You may return/exchange any items within 365 days from the original purchase date if you are not satisfied with your purchase, either for protocol related or product related problems.

>>This offer is only valid for products purchased directly from Adooq and its authorized distributors.

>>Prior to returning any items, please contact the Customer Service ([email protected]) to obtain an Return/Exchange Authorization. Items returned without prior authorization may not be accepted. Any items returned to Adooq should be in the original packaging and in the same condition as originally purchased.

Website: www.adooq.com
Order: [email protected]
(866)930-6790 (US & Canada)
+1-323-389-9269 (Outside of US & CAN)
(866)333-9607 (US & Canada)
+1-323-606-8156 (Outside of US & CAN)
[email protected]

High Purity Kinase Inhibitors on Signaling Pathways

Copyright© 2006-2017 Adooq BioScience LLC, All Rights Reserved.
4000 Barranca Parkway, Suite 250, Irvine, CA 92604 USA. Tel: 855-930-6790